CliffBio
biologic

Palynziq

pegvaliase-pqpz

Loss of exclusivityMay 2030projected — 12-year biologic exclusivity estimate
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand namePalynziq
Active ingredientpegvaliase-pqpz
Strength20MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2018
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Palynziq patent cliff — loss of exclusivity May 2030 | CliffBio